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Declines in Pediatric Bacterial Meningitis in the Republic 
of Benin Following Introduction of Pneumococcal 
Conjugate Vaccine: Epidemiological and Etiological 
Findings, 2011–2016
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Background. Pediatric bacterial meningitis (PBM) remains an important cause of disease in children in Africa. We describe 
findings from sentinel site bacterial meningitis surveillance in children <5 years of age in the Republic of Benin, 2011–2016.
Methods. Cerebrospinal fluid (CSF) was collected from children admitted to Parakou, Natitingou, and Tanguieta sentinel 
hospitals with suspected meningitis. Identification of Streptococcus pneumoniae (pneumococcus), Haemophilus influenzae, and 
Neisseria meningitidis (meningococcus) was performed by rapid diagnostic tests, microbiological culture, and/or polymerase chain 
reaction; where possible, serotyping/grouping was performed.
Results. A total of 10 919 suspected cases of meningitis were admitted to the sentinel hospitals. Most patients were 0–11 months 
old (4863 [44.5%]) and there were 542 (5.0%) in-hospital deaths. Overall, 4168 CSF samples were screened for pathogens and a total 
of 194 (4.7%) PBM cases were confirmed, predominantly caused by pneumococcus (98 [50.5%]). Following pneumococcal conjugate 
vaccine (PCV) introduction in 2011, annual suspected meningitis cases and deaths (case fatality rate) progressively declined from 
2534 to 1359 and from 164 (6.5%) to 14 (1.0%) in 2012 and 2016, respectively (P < .001). Additionally, there was a gradual decline in 
the proportion of meningitis cases caused by pneumococcus, from 77.3% (17/22) in 2011 to 32.4% (11/34) in 2016 (odds ratio, 7.11 
[95% confidence interval, 2.08–24.30]). Haemophilus influenzae meningitis fluctuated over the surveillance period and was the pre-
dominant pathogen (16/34 [47.1%]) by 2016.
Conclusions. The observed decrease in pneumococcal meningitis after PCV introduction may be indicative of changing patterns 
of PBM etiology in Benin. Maintaining vigilant and effective surveillance is critical for understanding these changes and their wider 
public health implications.
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Invasive bacterial disease, particularly bacterial meningitis, re-
mains an important cause of morbidity and mortality in devel-
oping countries [1]. Globally, the burden of bacterial meningitis 
is heaviest across the African meningitis belt, a region in sub- 
Saharan Africa spanning from Senegal to Ethiopia. Outbreaks 
of epidemic bacterial meningitis occur in this region frequently 
and are associated with high death tolls [2–4]. For instance, 
an outbreak affecting 10 countries, including the Republic of 
Benin, occurred in 2012, with an estimated case fatality rate 
(CFR) of 8.2% [5]. The public health significance of bacterial 
meningitis extends beyond mortality, as survivors are often left 
with life-changing sequelae [6, 7]. Previous reports estimated 
that half of all surviving children have lifelong neurologic im-
pairment including deafness, learning disabilities, and seizures 
[8, 9].
Bacterial meningitis is predominately caused by 3 pathogens, 
Neisseria meningitidis (meningococcus), Streptococcus 
pneumoniae (pneumococcus), or Haemophilus influenzae, and 
can be successfully prevented by immunization. Thus, organi-
zations such as Gavi, the Vaccine Alliance have funded the in-
troduction of the pneumococcal conjugate vaccines (PCVs), 
H.  influenzae type b (Hib) vaccine, and a meningococcal 
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conjugate vaccine (MenAfriVac) in a number of countries 
across sub-Saharan Africa [10–12]. Consequently, it is expected 
that the magnitude and severity of meningitis outbreaks in this 
region should begin to decline. However, monitoring the im-
pact of vaccine introduction remains a challenge in these coun-
tries, mostly due to weak disease surveillance systems [13].
Therefore, as part of the World Health Organization (WHO) 
Invasive Bacterial Vaccine-Preventable Disease (IB-VPD) sur-
veillance network, the Medical Research Council Unit The 
Gambia (MRCG) was designated as a regional reference lab-
oratory and a WHO Collaborating Centre (CC) to support the 
surveillance of pediatric bacterial meningitis (PBM) across 
countries in West and Central Africa. This includes the Republic 
of Benin, where the Hib vaccine and 13-valent PCV (PCV13) 
were introduced in 2005 and 2011 with coverage as high as 90% 
and 75%, respectively [14]. In addition, a mass MenAfriVac 
vaccination campaign took place in the northern parts of the 
Republic of Benin in late 2012 [15, 16]. Here, we describe the 
epidemiology and etiology of bacterial meningitis in children 
<5 years old, after longitudinal surveillance from 2011 through 
2016, in the Republic of Benin.
METHODS
Surveillance Design
The Republic of Benin is located in Western Africa, with a total 
land area of 112 622 km2 and an estimated population of 11.5 
million. Temperatures range from 24°C to 31°C with a dry 
season occurring from December to April and a rainy season 
from April to late July, then September to November, thus a 
bimodal rainfall pattern. National prevalence for human im-
munodeficiency virus (HIV) in Benin during the surveillance 
period was between 1.0% (2016) and 1.2% (2011) [17].
Hospital-based surveillance was conducted at 3 hospitals, 
the Centre Hospitalier Universitaire Départemental du Borgou/
Alibori in Parakou, L’hopital Saint Jean de Dieu de Tanguieta 
and the Centre Hospitalier Départemental de l’Atacoralocated 
in Natitingou, located in northern Benin. These hospitals serve 
as referral centers, receiving patients referred from other health 
facilities within and outside the city as well as self-referred 
patients who are seen at the emergency department or the out-
patient clinics. Both hospitals also provide 24-hour emergency 
medical care to the public including for patients with suspected 
meningitis.
Case Enrollment
Standardized guidelines including case definitions and labora-
tory protocols developed by the WHO were applied during the 
surveillance period [18]. All cases of suspected meningitis in 
children aged <5 years admitted to the sentinel hospitals during 
the surveillance period were enrolled. Cerebrospinal fluid (CSF) 
was collected at the time of admission or soon after, as part of 
routine clinical evaluation. The WHO clinical case definition 
for suspected meningitis, defined as sudden onset of fever 
(>38°C axillary or >38.5°C rectal temperature), and 1 or more 
of any the following clinical symptoms: altered consciousness, 
neck stiffness, sensitivity to light, and bulging of the fontanelle 
if <1 year old, was applied throughout the surveillance period.
Laboratory Diagnostics at the Sentinel Hospitals
CSF samples were sent to the Service National de Laboratoire 
Sante Publique in Cotonou, southern Benin, after macroscopic 
and microscopic examination of CSF was performed in the 
sentinel hospital laboratory. White blood cell (WBC) counts 
were performed using a Neubauer counting chamber, glucose 
concentrations were determined using the glucose oxidase 
method, and CSF protein levels were determined using the tri-
chloroacetic acid turbidimetric method, as previously described 
[19, 20]. Identification of pneumococcus, H.  influenzae, and 
meningococcus was determined by Gram staining, colony mor-
phology on appropriate agar plates, and rapid diagnostic tests 
(RDTs). The RDTs used included the Pastorex meningitis kit 
(Bio-Rad, United Kingdom) for pneumococcus, Hib, and me-
ningococcal serogroup A, B, C, Y, and W antigen detection and 
the BINAX NOW kit (Alere Inc) for pneumococcal antigen 
detection. All procedures were performed according to WHO 
standards [21].
Laboratory Diagnostics at the WHO CC, MRCG
Viable bacterial isolates and a proportion of CSF culture-
negative samples were sent to the WHO CC at MRCG for fur-
ther testing. Identification of pneumococcus, H.  influenzae, 
and meningococcus bacterial isolates were confirmed by 
colony morphology. Pneumococcal isolates were confirmed 
with optochin tests (5-μg optochin disk; Oxoid, Basingstoke, 
United Kingdom), and the analytical profile index (API NH; 
bioMérieux, United Kingdom) was used for confirmation of 
meningococcus and H.  influenzae isolates. Pneumococcal 
isolates were serotyped by latex agglutination using latex 
antisera (Statens Serum Institut, Copenhagen, Denmark) for 
detecting ≥90 pneumococcal serotypes, whereas H. influenzae 
isolates were serotyped using antisera for serotypes a to f 
(Murex Biotech, Dartford, United Kingdom), as described 
previously [22].
Real-time polymerase chain reaction (qPCR) was used for 
identification of pneumococcus, H.  influenzae, and meningo-
coccus, as previously described [2]. In brief, species-specific 
qPCR was performed targeting the autolysin gene (lytA), pro-
tein D encoding gene (hpd), and Cu, Zn superoxide dismutase 
gene (sodC) for the detection of pneumococcus, H. influenzae, 
and meningococcus, respectively. An RNase P gene assay was 
performed concurrently to assess the integrity of the CSF 
samples. Cycle threshold (Ct) values of ≤36 were considered 
positive results.
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Haemophilus influenzae serotyping was performed by qPCR 
targeting acsB, bcsB, ccsD, dscE, ecsH, and bexD genes for the 
identification of serotypes a–f, respectively. Meningococcal 
serogroups were determined targeting sacB, synD, synE, synG, 
xcbB, and synF for identification of serogroups A, B, C, W, 
X, and Y, respectively. Ct values of ≤36 were considered pos-
itive. For pneumococcal serotyping, nucleic acid extraction 
of CSF samples was performed using the Qiagen DNA kit 
(Qiagen, Crawley, United Kingdom), and a sequential triplex 
qPCR assay, which detects 21 serotypes commonly isolated in 
Africa, was performed. Ct values of ≤36 were considered posi-
tive. Pneumococci that could not be typed, with Ct values >32, 
were further subjected to sequential conventional multiplex 
serotyping PCRs.
Statistical Analysis
All statistical analysis was carried out using Stata software ver-
sion 12 (StataCorp, College Station, Texas). Associations be-
tween selected clinical symptoms and sequelae or pathogen 
detection by qPCR were determined using a χ 2 test. A P value 
<.05 indicates statistical significance. Significant associations 
were subjected to logistic regression to estimate the direction 
of association.
Ethical considerations
Ethical approval was not a requirement in Benin for routine 
meningitis surveillance, including drug susceptibility testing 
of collected isolates, as this was approved as part of the rou-
tine diagnostic algorithm at the Ministry of Health. However, 
informed consent was sought from the parents or guardians 
of the surveillance participants. Additionally, the surveillance 
received overarching ethical approval (SCC1188) by the joint 
Medical Research Council (MRC)/The Gambia government 
ethics board that allowed the analysis of collected West African 
isolates at MRCG.
RESULTS
Demographic and Clinical Characteristics
A total of 10  919 children with suspected meningitis were 
admitted at the sentinel hospitals from 2011 through 2016. 
Overall, 5888 (53.9%) patients were male and the median age 
of patients was 22 months (interquartile range, 1–23 months; 
Table 1). More than two-fifths of patients with suspected men-
ingitis (4863 [44.5%]) were aged 0–11 months.
In-hospital deaths accounted for 542 patients (CFR, 5.0%), 
whereas 7652 (70.1%) children were discharged from hos-
pital alive and discharge status data were unavailable for 2725 
(24.9%). Of these 542 patients, children aged 24–59  months 
accounted for most deaths (241 [44.5%]), followed by those 
aged 0–11  months (184 [33.9%]). There were more deaths in 
male children than in females (285 [52.6%] vs 252 [46.5%]; 
P  =  .04). Additionally, only 58 of 7652 (0.8%) patients who 
survived were reported to have lasting sequelae at the time of 
hospital discharge, including hearing loss and limb weakness, 
whereas 2128 (27.8%) had no sequelae and 5466 (71.4%) had 
missing data on sequelae.
The annual distribution of admission outcomes over the sur-
veillance period showed a progressive decline in both the total 
number of suspected cases per year (2534 in 2012 to 1359 in 
2016) and the number of deaths (164 [CFR, 6.5%] in 2012 to 
Table 1. Summary of Patient Characteristics With Suspected Bacterial Meningitis in the Republic of Benin, 2011–2016
Characteristic All Suspected Cases, No. (%) CSF Specimen Collected, No. (%) CSF Specimen Not Collected, No. (%) P Valuea
Age
 0–11 mo 4863 (44.5) 1788 (42.9) 3075 (45.5) .26
 12–23 mo 2038 (18.7) 772 (18.5) 1266 (18.8)  
 24–59 mo 3826 (35.0) 1496 (35.9) 2330 (34.5)  
 Unknown 192 (1.8) 112 (2.7) 80 (1.2)  
Sex
 Male 5888 (53.9) 2224 (53.4) 3664 (54.3) .38
 Female 4929 (45.1) 1888 (45.3) 3041 (45.0)  
 Unknown 102 (0.9) 56 (1.3) 46 (0.7)  
Antibiotics before admission
 Yes 997 (9.1) 472 (11.3) 525 (7.8) .08
 No 4641 (42.5) 1837 (44.1) 2804 (41.5)  
 Unknown 5281 (48.4) 1859 (44.6) 3422 (50.7)  
Outcome
 Discharged alive 7652 (70.1) 2762 (66.3) 4890 (72.4) .07
 Died 542 (5.0) 131 (3.1) 411 (6.1)  
 Unknown 2725 (25.0) 1275 (30.6) 1450 (21.5)  
 Total suspected casesb 10 919 (100.0) 4168 (100.0) 6751 (100.0)  
Abbreviation: CSF, cerebrospinal fluid.
aComparison between suspected cases from whom CSF specimens were collected and those in whom no specimen was collected.
bSuspected cases include cases that were defined as probable as per World Health Organization case definition guidelines [18].
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14 [CFR, 1.0%] in 2016; P < .001), following the introduction of 
PCV13 in 2011 (Figure 1). Analysis of cases admitted by month 
highlighted an annual pattern of admissions, peaking during 
the cooler dry season from July to September (Figure 2).
A total of 4168 CSF samples from patients with suspected 
PBM were tested and a bacterial pathogen was detected in 194 
(4.7%), confirmed to be either pneumococcus, H.  influenzae, 
or meningococcus. The majority of these CSF samples (74.6% 
[3110/  4168]) were reported to be clear, whereas 4.4% (182) 
were turbid (Table 2). However, the proportion of turbid CSF 
specimens that had a pathogen detected was up to 10 times 
higher than in CSF samples with other appearances including, 
clear, blood-stained, and xanthochromic (48.9% in turbid CSF 
vs <5% for other CSF specimen types). Additionally, the pro-
portion of pathogens identified was highest in CSF samples 
with WBC counts of >100 cells/μL (14.0%) and lowest in CSF 
samples with lower WBC counts of <10 cells/μL (2.7%).
Pathogen Distribution
Of the 194 pathogens detected, pneumococcus was the predom-
inant pathogen, accounting for 98 cases (50.5%). Haemophilus 
influenzae and meningococcus accounted for a quarter each 
(48 cases [24.7%]) of all positive samples (Table 3). When 
disaggregated by year, a gradual decline in the proportion of 
pathogens identified was observed. Pneumococcus decreased 
from 77.3% (17/22) in 2011 to 32.4% (11/34) in 2016 (odds 
ratio, 7.11 [95% confidence interval, 2.08–24.30]). In contrast, 
the proportion of H. influenzae appeared to fluctuate over the 
same time period and, by 2016, it was the predominant path-
ogen (16/34 [47.1%]) identified among positive CSF samples 
(Table 3).
Pneumococcal serotyping was performed on 40 of 98 pos-
itive CSF samples collected from 2011 to 2016. Prevalence of 
vaccine-type serotypes (VTs) and nonvaccine-type serotypes 
(NVTs) fluctuated from year to year, thus showing no clear pat-
tern of NVT replacement post–PCV13 introduction. Of the 40 
pneumococcal isolates for which serotyping was performed, 
proportions of VT and NVT serotypes identified during the 
surveillance period were, respectively, 66.7% and 33.3% in 2011; 
54.5% and 45.5% in 2012; 66.7% and 33.3% in 2013; 40.0% and 
60.0% in 2014; 83.0% and 17.0% in 2015; and 33.3% and 66.7% 
in 2016. The predominant VTs were serotypes 6 (10/59 [16.9%]) 
and serotypes 14 and 18C (3/40 each [7.5%]), whereas the pre-
dominant NVT was serotype 12 (5/40 [12.5%]). Of the 98 cases 
of pneumococcal meningitis, only 4 (4.1%) had received PCV13 
vaccination, whereas vaccination data for the remaining 94 
(95.9%) were unavailable. Of these 4, serotyping was confirmed 
for 1 case and was found to be an NVT (35B).
Serotyping was performed on 15 of 48 of H.  influenzae–
positive CSF samples collected from 2013 to 2016. A  total of 
3 Hib isolates were identified, 1 in 2013 and 2 in 2016. Hib 
vaccine data for these cases were unavailable. Meningococcal 
serogrouping was performed on 16 of 48 positive CSF samples 
collected from 2012 to 2016. Approximately, one-third of me-
ningococcal isolates were nongroupable by PCR (5/16 [31.3%]), 
whereas the majority of those grouped belonged to the W (4/16 
[25.0%]), X (3/16 [18.8%]), and A (2/16 [12.5%]) serogroups.
DISCUSSION
Here, we highlight bacterial causes of pediatric meningitis over 
a 6-year period, including the period following the introduc-
tion of Hib and PCVs in the Republic of Benin. In particular, 
we report on progressive declines in the total numbers of men-
ingitis cases and in the prevalence of pneumococcal menin-
gitis following introduction of PCVs in the Republic of Benin. 
Also, relevant epidemiological findings from PBM cases were 
reviewed, thus, providing a clinical and demographic context 
for interpretation of the laboratory results.
Figure 1. Yearly distribution of outcomes for suspected meningitis cases admitted to hospital in the Republic of Benin, 2011–2016.
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Pneumococcus was the predominant pathogen identified 
throughout the surveillance period, even though the prevalence 
was seen to progressively decline in the post-PCV era. This de-
crease in prevalence of pneumococcal meningitis appeared to 
mirror the progressive declines in total numbers of meningitis 
cases reported during the same time period. Declining rates 
of invasive pneumococcal disease, including pneumococcal 
meningitis, following PCV introduction have been reported 
elsewhere [23–25]. In these earlier studies, the decline in disease 
was attributed to decreases in prevalence of pneumococcal VT 
serotypes, following PCV introduction [23, 25]. The same trend 
was not observed in the current report, where the number of 
pneumococcal meningitis cases caused by both VT and NVT 
serotypes fluctuated by year. Also, we were not able to assess 
the likely impact of other possible explanations for the declines 
in overall meningitis cases observed during this surveillance 
period, such as any year-to-year changes in the patterns of 
viral infections or possible impact of introduction of antire-
troviral therapy programs across the country. The prevalence 
of HIV in Benin remained relatively low (1.2% in 2011; 1.0% 
in 2016) throughout the surveillance period, and it is unlikely 
that this may have had an influence on the observed declines in 
meningitis cases during this period [17]. Although it has not 
been possible to rule out the influence of other interventions 
on prevalence of meningitis during this surveillance period, 
our findings provide some indication of the likely impact of 
PCV introduction on meningitis in this setting. This report also 
highlights the need for ongoing surveillance to provide robust 
data for the evaluation of vaccine impact in the post-PCV era.
Serotype replacement of VT serotypes with NVT serotypes 
has been reported in other settings [26, 27]. Our results did not 
provide clear evidence of serotype replacement following PCV in-
troduction. However, less than half (41.7%) of the recovered pneu-
mococcal isolates were serotyped. Thus, the extent to which our 
findings represent the true proportions of pneumococcal menin-
gitis caused by VT and NVT serotypes in a pre- and post-PCV era 
is limited. Serogroup 12 was identified as the predominant NVT 
during the surveillance period. Serotype 12F has been reported 
to be an important replacement serotype and has been associated 
with epidemic outbreaks in parts of North America and Europe 
Figure 2. Distribution of pathogens isolated and suspected meningitis cases admitted to hospital in the Republic of Benin by month and year for the period 2011–2016.
Table 2. Distribution of Cerebrospinal Fluid Characteristics and 
Proportion of Pathogen Identified by Any Laboratory Method in the 
Republic of Benin, 2011–2016
Characteristic No. (%) No. of Pathogens (%)
CSF appearance   
 Clear 3110 (74.6) 78 (2.5)
 Turbid/cloudy 182 (4.4) 89 (48.9)
 Xanthrochromic 237 (5.7) 8 (3.4)
 Blood stained 413 (9.9) 8 (1.9)
 Unknown 226 (5.4) 11 (4.9)
WBC count, cells/μL   
 ≤10 3006 (72.1) 79 (2.6)
 >10 to 100 217 (5.2) 19 (8.8)
 >100 543 (13.0) 76 (14.0)
 Unknown 402 (9.6) 20 (5.0)
Protein, mg/dL   
 ≤100 439 (10.5) 26 (5.9)
 >100 238 (5.7) 11 (4.6)
 Unknown 3491 (83.8) 157 (4.5)
Glucose, g/dL   
 <40 545 (13.1) 31 (5.7)
 ≥40 1792 (43.0) 28 (1.6)
 Unknown 1831 (43.9) 135 (7.4)
Total CSF-tested suspected cases 4168 194 (4.7)
Abbreviations: CSF, cerebrospinal fluid; WBC, white blood cell.
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[28, 29]. More importantly, this serotype has similar characteris-
tics with serotype 1 and is commonly identified in invasive disease 
[28]. Given that serotype replacement has been shown in other 
countries within West Africa, where PCV has been introduced, 
our results indicate the need for continued monitoring of any 
changes in patterns of the predominant circulating pneumococcal 
serotypes and their potential to cause epidemics [23].
In contrast to declines in pneumococcal meningitis, preva-
lence of H. influenzae meningitis fluctuated during this surveil-
lance period, a finding that was unexpected, given the earlier 
introduction of the Hib conjugate vaccine in Benin in 2005 [14]. 
Reports from elsewhere have shown significant reductions in 
Hib-associated diseases following vaccination [30]. We note 
that only 3 cases of Hib meningitis were identified between 
2013 and 2016. These small numbers of Hib meningitis cases 
therefore make any suggestion of an increase in H. influenzae 
meningitis unlikely in this context. One report from The 
Gambia showed that there was reemergence of 5 cases of Hib 
disease in 2005–2006, 7 years after introduction of Hib vaccine 
in the country [31]. In that report, no evidence was found of 
the emergence of a hypervirulent strain, and the cause of the 
reemergence of Hib disease was not clear. In the current report, 
vaccination status of the 3 cases of Hib meningitis identified 
could not be established. It remains unclear if these 3 menin-
gitis cases represent unvaccinated cases, a failure of the vaccine, 
or emergence of vaccine escape variants of the pathogen [32]. 
Nonetheless, these findings reinforce the need for continued di-
sease surveillance following vaccine introduction both to assess 
vaccine impact and to enable early detection of any changing 
patterns in disease epidemiology.
Our results highlighted a seasonal pattern of the incidence 
of suspected bacterial meningitis cases within the Republic of 
Benin. The annual peaks during July to September contrast with 
previous reports on seasonality of meningitis in sub-Saharan 
Africa, where peaks in the dry months of November to March 
were observed [33]. This difference may have been influenced 
by a second dry season observed in the Republic of Benin from 
late July to early September. In addition, most other reports of 
disease seasonality are related to epidemic meningitis, which is 
different to the data presented in this paper. It is probable that 
our findings may be indicative of a different disease epidemi-
ology in Benin and may be helpful in guiding the timing of 
interventions for effective control of meningitis.
Globally, rates of mortality from bacterial meningitis have 
varied depending on the regions of the world. Mortality in 
industrialized country setting has been much lower in com-
parison to reports from developing country settings such as in 
Africa and Latin America, where mortality rates as high as 37% 
have been recorded and the meningitis disease burden is dis-
proportionately heavier [34–36]. Also, when pathogen-specific 
mortality is considered, pneumococcal meningitis has been re-
ported to have the highest CFR globally, with rates of up to 45% 
in Africa [37–40]. Thus, our estimated CFR of 5% appears low 
in comparison to these previous reports from similar geograph-
ical settings. However, our estimate has been generated from 
available routine medical records, which were often incomplete. 
For example, the outcome at discharge status was unavailable 
for 25% of patients with suspected meningitis. Thus, the esti-
mate presented in this report could potentially represent an un-
derestimate of the true CFRs observed during the surveillance 
period.
Young children have previously been identified as having a 
higher risk of meningitis and of poorer outcomes in compar-
ison to other age groups [41]. Similar findings were observed 
during our surveillance, highlighting the need for prevention 
and treatment strategies that are targeted at these high-risk 
groups. These strategies include the use of vaccines that are 
immunogenic in infancy and the application of case detection 
protocols that enable early identification of bacterial meningitis 
among young children. In addition, the risk of bacterial men-
ingitis has been shown to be higher in people living with HIV, 
with 1 report showing an increased risk of as much as 8.3 times 
than seen in the general population [42, 43]. Also, etiological 
agents of meningitis in persons infected with HIV have been 
found to differ from those in HIV-uninfected individuals [42, 
44]. As a low-HIV setting with national HIV prevalence rates of 
Table 3. Yearly Distribution of Bacterial Meningitis Pathogens in the Republic of Benin, 2011–2016
Year CSF Samples Tested, No.
Pathogens Identified Pneumococcus Haemophilus influenzae Meningococcus
No. No. (%)a No. (%)a No. (%)a
2011 184 22 17 (77.3) 3 (13.6) 2 (9.1)
2012 105 39 21 (53.8) 5 (12.8) 13 (33.3)
2013 283 64 29 (45.3) 16 (25.0) 19 (29.7)
2014 1069 18 10 (55.6) 4 (22.2) 4 (22.2)
2015 1252 17 10 (58.8) 4 (23.5) 3 (17.6)
2016 1275 34 11 (32.4) 16 (47.1) 7 (20.6)
Total 4168 194 98 (50.5) 48 (24.7) 48 (24.7)
Abbreviation: CSF, cerebrospinal fluid.
aPercentages for each pathogen were calculated based on the total number of pathogens identified for each year.
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between 1.0% and 1.2% reported during the surveillance period 
in Benin, the impact of HIV on meningitis would be expected 
to be much lower than would be seen in a setting of high HIV 
prevalence [17]. However, the current report is unable to di-
rectly assess the influence of HIV on meningitis risk or on the 
etiological agents identified, as data on HIV status of children 
included in this surveillance were unavailable.
We acknowledge some limitations to our surveillance, within 
the Republic of Benin, that may limit generalization of the 
findings. For example, surveillance was only carried out within 
the context of routine clinical settings, and both clinical and 
demographic data were incomplete for some key outcomes of 
interest. In particular, data on discharge outcomes, including 
sequelae and PCV and Hib vaccination data, were unavailable 
for a large percentage of the children included in this survey, 
thus limiting our ability to assess the relevance of these factors 
to the risk for meningitis. Also, the numbers of reported cases 
in the early years of the surveillance were quite small, CSF 
samples were not available for analysis for more than half of the 
patients enrolled at sentinel hospitals, and serotyping/grouping 
analysis was limited. However, our results indicate that the chil-
dren from whom CSF samples were collected and who have 
been included in this analysis were demographically similar to 
those suspected cases for whom a CSF specimen was not avail-
able. Nonetheless, continued disease surveillance using strictly 
monitored standards, as applied by the WHO CC, would allow 
robust data to be collected in the long term and aid our under-
standing of the observed changes.
CONCLUSIONS
Overall, pneumococcus has remained an important cause of 
childhood meningitis in the Republic of Benin, even though 
there was a progressive decline in its prevalence and relative 
contribution among other meningitis-causing pathogens in the 
post-PCV era. Over the same period, a concomitant increase in 
the prevalence of H. influenzae disease, with only 3 cases of Hib 
meningitis identified, suggests the need for closer monitoring 
to determine any changes in disease patterns a decade after in-
troduction of the Hib vaccine. This report highlights a clear 
need for ongoing surveillance for early detection of changing 
patterns to the etiology and epidemiology of PBM in the West 
Africa subregion.
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